Ignite Creation Date:
2024-05-06 @ 7:42 PM
Last Modification Date:
2024-10-26 @ 3:12 PM
Study NCT ID:
NCT06102772
Status:
RECRUITING
Last Update Posted:
2023-10-26
First Post:
2023-10-22
Brief Title:
Adebrelimab and Fruquintinib Combined With PaclitaxelAlbumin Paclitaxel for Advanced Gastric Cancer
Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Organization:
Tianjin Medical University Cancer Institute and Hospital
Study Overview
Official Title:
Phase II Clinical Study of Adebrelimab and Fruquintinib Combined With PaclitaxelAlbumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer
Status:
RECRUITING
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a prospective single-center open single-arm clinical study to observe and evaluate the efficacy and safety of Fruquintinib and Adebrelimab combined with paclitaxelalbumin paclitaxel for second-line treatment of advanced gastric cancer
Detailed Description:
The benefits of immunotherapy in first-line treatment for gastric cancer patients whose tumor tissue CPS5 are limited And some patients have not been treated by immunotherapy in the first-line treatment in clinical practice This study intends to enroll first-line patients with advanced gastric cancer who have not been treated with PD-1 antibody and explore the effectiveness and safety of second-line PD-L1 antibody combined with Fruquintinib and paclitaxelalbumin-paclitaxel providing clues for the application of PD-L1 antibody in advanced gastric cancer
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None